Regional Adipose Tissue Characteristics in Type II Diabetes

Launched by CONCORDIA UNIVERSITY, MONTREAL · Sep 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how fat tissue behaves in different parts of the body, particularly in people with obesity and type 2 diabetes. Researchers want to understand how the fat stored in the abdomen might lead to health problems like diabetes and heart disease, and how these health issues might change the fat itself. To do this, they are looking for 140 participants aged 18 to 65, including those with obesity, those with diabetes, and healthy individuals with normal weight. Participants will be recruited from a hospital in Montreal and the surrounding community, especially those who are planning to have surgery.

To be eligible for the trial, participants should be men or women between 18 and 65 years old, and they should be scheduled for either bariatric surgery (for those with obesity) or general abdominal surgery (for those with normal weight). It's important that individuals with obesity have a body mass index (BMI) of 30 or higher and have maintained their weight for at least two months before the study. There are some exclusions, such as smoking or having certain medical conditions that might interfere with the research. Participants can expect to contribute to important research that could help improve understanding of diabetes and obesity-related health issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men, premenopausal and postmenopausal females between 18-65 years
• • Anticipating having bariatric surgery (participants with obesity) or general surgery in the abdominal area (normal weight participants) with a duration of less than 1.5 hours.
• • BMI 30 kg / m2 (participants with obesity)
• • Weight Stable for a minimum of two months prior to the first pre-op visit
• Exclusion Criteria:
• • Smoking
• • Renal impairment defined by creatinine clearance; 60 ml/minute
• • Uncontrolled hypothyroidism
• • No comorbidity other than diabetes type II Exceptions: controlled hypertension, hypothyroidism controlled, controlled dyslipidemia
• • Use prescribed medication that affect our outcomes E.g. Exceptions include metformin, DPP-4 inhibitors, inhibitors of the α-glucosidase, hypotensive with a stable dose for 3 months lipid lowering with a stable dose for 3 months.